Astellas Pharma US Inc. to Pay $7.3 Million to Resolve False Claims Act Allegations Relating to Marketing of Drug Mycamine
Astellas Pharma US Inc. to Pay $7.3 Million to Resolve False
Claims Act Allegations Relating to Marketing of Drug Mycamine
Pharmaceutical company Astellas Pharma US Inc. will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use.